This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.
A randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
213
Applied topically twice daily
Applied topically daily
Applied topically twice and once daily
Qst acne site #1
Hot Springs, Arkansas, United States
QST Site #118
Encinitas, California, United States
Absolute Change in Inflammatory Lesion Counts
Change in inflammatory lesion count from Baseline to Week 12
Time frame: Baseline and Week 12
Absolute Change in Non-inflammatory Lesion Counts
Absolute Change in non-inflammatory lesion count from Baseline to Week 12
Time frame: Baseline and Week 12
Proportion of Success According to the Dichotomized Investigator Global Assessment [IGA] at End of Treatment
Proportion of subjects at end of treatment achieving IGA of 'clear' or 'almost clear' and a change of at least 2 in the IGA from baseline. The IGA was a static assessment. The assessment was made with the evaluator approximately 3 feet away from the subject; the IGA assessment was to be done prior to the lesion counts. A lower grade is considered to be a better outcome. Grade 0 = clear (clear skin with no inflammatory or non-inflammatory lesions) Grade 1 = almost clear (few non-inflammatory lesions with no more than rare papules (papules may be resolving and hyperpigmented, though not pink-red) Grade 2 = mild (some non-inflammatory lesions with no more than a few inflammatory lesions) Grade 3 = moderate (up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 nodular lesion) Grade 4= severe (up to many non-inflammatory and inflammatory lesions, including nodular lesions)
Time frame: Baseline and Week 12
Percent Change in Inflammatory Lesion Count From Baseline to Week 12
The percent change in inflammatory lesion count from Baseline to Week 12
Time frame: Baseline and Week 12
Percent Change in Non-inflammatory Lesion Count From Baseline to Week 12
The percent change in non-inflammatory lesion count from Baseline to Week 12
Time frame: Baseline and Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
QST Site #111
San Diego, California, United States
QST Site #113
San Diego, California, United States
QST Site #119
Santa Monica, California, United States
QST Site #103
Boca Raton, Florida, United States
QST Site # 110
Pinellas Park, Florida, United States
QST Site # 116
Newnan, Georgia, United States
QST Site #117
Louisville, Kentucky, United States
QST Site #112
Detroit, Michigan, United States
...and 10 more locations
Median Time to Improvement
Median time to a 35% improvement in inflammatory lesion counts (Kaplan-Meier estimate). The full range values presented below are estimates made from the Kaplan-Meier figure.
Time frame: Baseline through Week 12